Dyadic: Rises on expanding partnership to make COVID-19 vaccines for variants

Medy-Tox

22/03/2021 13:18

** Biotech co's shares  DYAI.O  rise 38.8% to $7.40
premarket
    ** Dyadic says expanding existing COVID-19 vaccine research
collaboration with South Korea's Medytox Inc  086900.KQ  to
co-develop COVID-19 vaccines/boosters based on a new platform
    ** Says vaccines to immunize people against two or more of
the current and future COVID-19 variants  urn:newsml:reuters.com:*:nGNX3y7ppF 
    ** Says new vaccines and boosters to be based on co's C1
technology - a gene expression platform based on a fungus named
C1
    ** C1 microorganism enables large-scale manufacture of
low-cost proteins, which may help speed up development and lower
production costs of vaccines and drugs - DYAI    
    ** Exclusive license for South Korea and Southeast Asian
countries if successful - co
    ** Up to last close, DYAI stock down about 1% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))